학술논문
A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk
Document Type
article
Author
Travis, Ruth C; Appleby, Paul N; Martin, Richard M; Holly, Jeff MP; Albanes, Demetrius; Black, Amanda; Bueno-de-Mesquita, HB As; Chan, June M; Chen, Chu; Chirlaque, Maria-Dolores; Cook, Michael B; Deschasaux, Mélanie; Donovan, Jenny L; Ferrucci, Luigi; Galan, Pilar; Giles, Graham G; Giovannucci, Edward L; Gunter, Marc J; Habel, Laurel A; Hamdy, Freddie C; Helzlsouer, Kathy J; Hercberg, Serge; Hoover, Robert N; Janssen, Joseph AMJL; Kaaks, Rudolf; Kubo, Tatsuhiko; Le Marchand, Loic; Metter, E Jeffrey; Mikami, Kazuya; Morris, Joan K; Neal, David E; Neuhouser, Marian L; Ozasa, Kotaro; Palli, Domenico; Platz, Elizabeth A; Pollak, Michael; Price, Alison J; Roobol, Monique J; Schaefer, Catherine; Schenk, Jeannette M; Severi, Gianluca; Stampfer, Meir J; Stattin, Pär; Tamakoshi, Akiko; Tangen, Catherine M; Touvier, Mathilde; Wald, Nicholas J; Weiss, Noel S; Ziegler, Regina G; Key, Timothy J; Allen, Naomi E
Source
Cancer Research. 76(8)
Subject
Language
Abstract
The role of insulin-like growth factors (IGF) in prostate cancer development is not fully understood. To investigate the association between circulating concentrations of IGFs (IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3) and prostate cancer risk, we pooled individual participant data from 17 prospective and two cross-sectional studies, including up to 10,554 prostate cancer cases and 13,618 control participants. Conditional logistic regression was used to estimate the ORs for prostate cancer based on the study-specific fifth of each analyte. Overall, IGF-I, IGF-II, IGFBP-2, and IGFBP-3 concentrations were positively associated with prostate cancer risk (Ptrend all ≤ 0.005), and IGFBP-1 was inversely associated weakly with risk (Ptrend = 0.05). However, heterogeneity between the prospective and cross-sectional studies was evident (Pheterogeneity = 0.03), unless the analyses were restricted to prospective studies (with the exception of IGF-II, Pheterogeneity = 0.02). For prospective studies, the OR for men in the highest versus the lowest fifth of each analyte was 1.29 (95% confidence interval, 1.16-1.43) for IGF-I, 0.81 (0.68-0.96) for IGFBP-1, and 1.25 (1.12-1.40) for IGFBP-3. These associations did not differ significantly by time-to-diagnosis or tumor stage or grade. After mutual adjustment for each of the other analytes, only IGF-I remained associated with risk. Our collaborative study represents the largest pooled analysis of the relationship between prostate cancer risk and circulating concentrations of IGF-I, providing strong evidence that IGF-I is highly likely to be involved in prostate cancer development. Cancer Res; 76(8); 2288-300. ©2016 AACR.